Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2001 Aug;10(4):191–197. doi: 10.1080/09629350123387

Tumor necrosis factor-alpha/interleukin-10 balance in normal and cystic fibrosis children.

G V Shmarina 1, A L Pukhalsky 1, S N Kokarovtseva 1, D A Pukhalskaya 1, L A Shabalova 1, N I Kapranov 1, N J Kashirskaja 1
PMCID: PMC1781714  PMID: 11577995

Abstract

BACKGROUND: The balance between tumor necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10) is important for immune homeostasis maintenance. Exuberant production of TNF-alpha contributes to overwhelming inflammatory response and tissue damage. But, commonly, increase in TNF-alpha is counterbalanced by simultaneous synthesis of an anti-inflammatory cytokine IL-10, which suppresses production of many activating and regulatory mediators. AIMS: In the present study, the relationships between TNF-alpha and IL-10 in the plasma of healthy school-children and cystic fibrosis (CF) patients have been investigated. METHODS: Blood samples were obtained from 12 CF patients with chronic pulmonary disease and 18 healthy schoolchildren vaccinated with live attenuated rubella vaccine. IL-10 and TNF-alpha were determined in the plasma samples using commercially available enzyme-linked immunosorbent assay kits. RESULTS: Before vaccination, most healthy children (13 of 18) demonstrated superiority of pro-inflammatory TNF-alpha over anti-inflammatory IL-10 (TNF-alpha/IL-10 > 1). In these subjects, a significant positive linear association between the cytokine values has been found. Vaccine challenge resulted in a marked reduction of TNF-alpha/IL-10 ratios. In addition, a disappearance of correlation between the cytokine values was observed. Such disturbance was related to exuberant elevation of the IL-10 levels after inoculation. On the contrary, in CF individuals, plasma cytokine values remained in strong linear association independently of TNF-alpha or IL-10 predominance. No spikes in the plasma levels of IL-10 in CF patients during a 6-month observation period have been revealed. CONCLUSIONS: There were no fundamental differences between CF and healthy children in the regulation of TNF-alpha and IL-10 secretion. Thus, immune quiescence seemed to be associated with the predominance of TNF-alpha, whereas immune disturbance was characterized by IL-10 superiority. The only abnormality that was found in CF patients consisted of their inability to produce unlimitedly IL-10 in response to antigen stimuli.

Full Text

The Full Text of this article is available as a PDF (178.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggarwal B. B., Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw. 1996 Apr-Jun;7(2):93–124. [PubMed] [Google Scholar]
  2. Arispe N., Rojas E., Hartman J., Sorscher E. J., Pollard H. B. Intrinsic anion channel activity of the recombinant first nucleotide binding fold domain of the cystic fibrosis transmembrane regulator protein. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1539–1543. doi: 10.1073/pnas.89.5.1539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Armstrong L., Millar A. B. Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome. Thorax. 1997 May;52(5):442–446. doi: 10.1136/thx.52.5.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Arsenijevic D., Girardier L., Seydoux J., Pechere J. C., Garcia I., Lucas R., Chang H. R., Dulloo A. G. Metabolic-cytokine responses to a second immunological challenge with LPS in mice with T. gondii infection. Am J Physiol. 1998 Mar;274(3 Pt 1):E439–E445. doi: 10.1152/ajpendo.1998.274.3.E439. [DOI] [PubMed] [Google Scholar]
  5. Bear C. E., Li C. H., Kartner N., Bridges R. J., Jensen T. J., Ramjeesingh M., Riordan J. R. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell. 1992 Feb 21;68(4):809–818. doi: 10.1016/0092-8674(92)90155-6. [DOI] [PubMed] [Google Scholar]
  6. Bonfield T. L., Konstan M. W., Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol. 1999 Jul;104(1):72–78. doi: 10.1016/s0091-6749(99)70116-8. [DOI] [PubMed] [Google Scholar]
  7. Bonfield T. L., Panuska J. R., Konstan M. W., Hilliard K. A., Hilliard J. B., Ghnaim H., Berger M. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2111–2118. doi: 10.1164/ajrccm.152.6.8520783. [DOI] [PubMed] [Google Scholar]
  8. Breuer W., Kartner N., Riordan J. R., Cabantchik Z. I. Induction of expression of the cystic fibrosis transmembrane conductance regulator. J Biol Chem. 1992 May 25;267(15):10465–10469. [PubMed] [Google Scholar]
  9. Brouckaert P., Fiers W. Tumor necrosis factor and the systemic inflammatory response syndrome. Curr Top Microbiol Immunol. 1996;216:167–187. doi: 10.1007/978-3-642-80186-0_8. [DOI] [PubMed] [Google Scholar]
  10. Cheng S. H., Rich D. P., Marshall J., Gregory R. J., Welsh M. J., Smith A. E. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell. 1991 Sep 6;66(5):1027–1036. doi: 10.1016/0092-8674(91)90446-6. [DOI] [PubMed] [Google Scholar]
  11. Eigler A., Siegmund B., Emmerich U., Baumann K. H., Hartmann G., Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol. 1998 Jan;63(1):101–107. doi: 10.1002/jlb.63.1.101. [DOI] [PubMed] [Google Scholar]
  12. Elenkov I. J., Wilder R. L., Chrousos G. P., Vizi E. S. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000 Dec;52(4):595–638. [PubMed] [Google Scholar]
  13. Foey A. D., Parry S. L., Williams L. M., Feldmann M., Foxwell B. M., Brennan F. M. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol. 1998 Jan 15;160(2):920–928. [PubMed] [Google Scholar]
  14. Fong Y., Tracey K. J., Moldawer L. L., Hesse D. G., Manogue K. B., Kenney J. S., Lee A. T., Kuo G. C., Allison A. C., Lowry S. F. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989 Nov 1;170(5):1627–1633. doi: 10.1084/jem.170.5.1627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gamble J. R., Harlan J. M., Klebanoff S. J., Vadas M. A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8667–8671. doi: 10.1073/pnas.82.24.8667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ghezzi P., Sacco S., Agnello D., Marullo A., Caselli G., Bertini R. Lps induces IL-6 in the brain and in serum largely through TNF production. Cytokine. 2000 Aug;12(8):1205–1210. doi: 10.1006/cyto.2000.0697. [DOI] [PubMed] [Google Scholar]
  17. Gudmundsson G., Bosch A., Davidson B. L., Berg D. J., Hunninghake G. W. Interleukin-10 modulates the severity of hypersensitivity pneumonitis in mice. Am J Respir Cell Mol Biol. 1998 Nov;19(5):812–818. doi: 10.1165/ajrcmb.19.5.3153. [DOI] [PubMed] [Google Scholar]
  18. Hickey M. J., Issekutz A. C., Reinhardt P. H., Fedorak R. N., Kubes P. Endogenous interleukin-10 regulates hemodynamic parameters, leukocyte-endothelial cell interactions, and microvascular permeability during endotoxemia. Circ Res. 1998 Nov 30;83(11):1124–1131. doi: 10.1161/01.res.83.11.1124. [DOI] [PubMed] [Google Scholar]
  19. Huhn R. D., Pennline K., Radwanski E., Clarke L., Sabo R., Cutler D. L. Effects of single intravenous doses of recombinant human interleukin-10 on subsets of circulating leukocytes in humans. Immunopharmacology. 1999 Feb;41(2):109–117. doi: 10.1016/s0162-3109(98)00058-7. [DOI] [PubMed] [Google Scholar]
  20. Koch C., Høiby N. Pathogenesis of cystic fibrosis. Lancet. 1993 Apr 24;341(8852):1065–1069. doi: 10.1016/0140-6736(93)92422-p. [DOI] [PubMed] [Google Scholar]
  21. Konstan M. W., Hilliard K. A., Norvell T. M., Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994 Aug;150(2):448–454. doi: 10.1164/ajrccm.150.2.8049828. [DOI] [PubMed] [Google Scholar]
  22. Lafleur R. L., Abrahamsen M. S., Maheswaran S. K. The biphasic mRNA expression pattern of bovine interleukin-8 in Pasteurella haemolytica lipopolysaccharide-stimulated alveolar macrophages is primarily due to tumor necrosis factor alpha. Infect Immun. 1998 Sep;66(9):4087–4092. doi: 10.1128/iai.66.9.4087-4092.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Laichalk L. L., Danforth J. M., Standiford T. J. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol. 1996 Oct;15(4):181–187. doi: 10.1111/j.1574-695X.1996.tb00084.x. [DOI] [PubMed] [Google Scholar]
  24. McDonald R. A., Matthews R. P., Idzerda R. L., McKnight G. S. Basal expression of the cystic fibrosis transmembrane conductance regulator gene is dependent on protein kinase A activity. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7560–7564. doi: 10.1073/pnas.92.16.7560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Moore K. W., O'Garra A., de Waal Malefyt R., Vieira P., Mosmann T. R. Interleukin-10. Annu Rev Immunol. 1993;11:165–190. doi: 10.1146/annurev.iy.11.040193.001121. [DOI] [PubMed] [Google Scholar]
  26. Moss R. B., Bocian R. C., Hsu Y. P., Dong Y. J., Kemna M., Wei T., Gardner P. Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin Exp Immunol. 1996 Nov;106(2):374–388. doi: 10.1046/j.1365-2249.1996.d01-826.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Oswald I. P., Wynn T. A., Sher A., James S. L. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8676–8680. doi: 10.1073/pnas.89.18.8676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Platzer C., Meisel C., Vogt K., Platzer M., Volk H. D. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol. 1995 Apr;7(4):517–523. doi: 10.1093/intimm/7.4.517. [DOI] [PubMed] [Google Scholar]
  29. Steinhauser M. L., Hogaboam C. M., Kunkel S. L., Lukacs N. W., Strieter R. M., Standiford T. J. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol. 1999 Jan 1;162(1):392–399. [PubMed] [Google Scholar]
  30. Stordeur P., Goldman M. Interleukin-10 as a regulatory cytokine induced by cellular stress: molecular aspects. Int Rev Immunol. 1998;16(5-6):501–522. doi: 10.3109/08830189809043006. [DOI] [PubMed] [Google Scholar]
  31. Tan A. M., Ferrante A., Goh D. H., Roberton D. M., Cripps A. W. Activation of the neutrophil bactericidal activity for nontypable Haemophilus influenzae by tumor necrosis factor and lymphotoxin. Pediatr Res. 1995 Feb;37(2):155–159. doi: 10.1203/00006450-199502000-00005. [DOI] [PubMed] [Google Scholar]
  32. Van der Poll T., Lowry S. F. Epinephrine inhibits endotoxin-induced IL-1 beta production: roles of tumor necrosis factor-alpha and IL-10. Am J Physiol. 1997 Dec;273(6 Pt 2):R1885–R1890. doi: 10.1152/ajpregu.1997.273.6.R1885. [DOI] [PubMed] [Google Scholar]
  33. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411–452. doi: 10.1146/annurev.iy.10.040192.002211. [DOI] [PubMed] [Google Scholar]
  34. Walley K. R., Lukacs N. W., Standiford T. J., Strieter R. M., Kunkel S. L. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun. 1996 Nov;64(11):4733–4738. doi: 10.1128/iai.64.11.4733-4738.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wanidworanun C., Strober W. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol. 1993 Dec 15;151(12):6853–6861. [PubMed] [Google Scholar]
  36. Westwick J. K., Weitzel C., Minden A., Karin M., Brenner D. A. Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J Biol Chem. 1994 Oct 21;269(42):26396–26401. [PubMed] [Google Scholar]
  37. Wheeler W. B., Colten H. R. Cystic fibrosis: current approach to diagnosis and management. Pediatr Rev. 1988 Feb;9(8):241–248. doi: 10.1542/pir.9-8-241. [DOI] [PubMed] [Google Scholar]
  38. Woiciechowsky C., Schöning B., Lanksch W. R., Volk H. D., Döcke W. D. Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J Mol Med (Berl) 1999 Nov;77(11):769–780. doi: 10.1007/s001099900051. [DOI] [PubMed] [Google Scholar]
  39. van der Poll T., Marchant A., Buurman W. A., Berman L., Keogh C. V., Lazarus D. D., Nguyen L., Goldman M., Moldawer L. L., Lowry S. F. Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol. 1995 Dec 1;155(11):5397–5401. [PubMed] [Google Scholar]
  40. van der Poll T., Marchant A., Keogh C. V., Goldman M., Lowry S. F. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis. 1996 Nov;174(5):994–1000. doi: 10.1093/infdis/174.5.994. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES